Items Tagged ‘Info Type’

August 7th, 2014

Kyprolis Improves Progression-Free Survival in Multiple Myeloma

By

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide) and low-dose dexamethasone lived significantly longer without their disease worsening compared to patients treated with Revlimid and low-dose dexamethasone. Multiple myeloma is […]

View full entry

Tags: carfilzomib, Info Type, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


August 6th, 2014

FDA Accepts Supplemental New Drug Application for Jakafi and Priority Review Granted for the Treatment of Polycythemia Vera

By

The  U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Jakafi® (ruxolitinib) as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. PV is a myeloproliferative neoplasm (MPN) characterized by an overproduction of normal red […]

View full entry

Tags: Info Type, jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


November 22nd, 2013

Gazyva Approved for CLL

By

The U.S. Food and Drug Administration (FDA) has approved Gazyva™ (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer Society estimates that approximately 15,000 people will be diagnosed and 4,580 will die […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Info Type, Leukemia, News